Your browser doesn't support javascript.
loading
Research status and application prospect of a novel immune checkpoint TIGIT in the immunotherapy of multiple myeloma / 国际肿瘤学杂志
Article de Zh | WPRIM | ID: wpr-989533
Bibliothèque responsable: WPRO
ABSTRACT
T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is a new immune checkpoint protein. Studies have shown that TIGIT can cause dysfunction of immune cells, weaken the anti-tumor effect, thus leading to tumor immune tolerance and immune escape. Blocking TIGIT can reverse immune cell failure and exert anti-tumor effect, which is expected to become a new therapeutic target for multiple myeloma.
Mots clés
Texte intégral: 1 Indice: WPRIM langue: Zh Texte intégral: Journal of International Oncology Année: 2023 Type: Article
Texte intégral: 1 Indice: WPRIM langue: Zh Texte intégral: Journal of International Oncology Année: 2023 Type: Article